Corporate
Novo Nordisk Raises 2026 Sales Outlook as Obesity Drug Demand Outpaces Supply
Novo Nordisk beat third-quarter expectations and raised its 2026 sales outlook on obesity drug demand, with shares up about five percent.
Yaw Boateng0 min read
Search
1 result for “obesity drugs”